Dermatology (Basel, Switzerland) · 2026
One-Year Real-Life Data from Thai Patients with Moderate to Severe Plaque Psoriasis Treated with Secukinumab - Outcomes from the PROMPT Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Asawanonda Pravit, Chularojanamontri Leena, Chuamanochan Mati, Amornpinyo Warayuwadee, Pongcharoen Padcha, Laodheerasiri Supapat, Pattamadilok Bensachee, Choonhakarn Charoen, Sangmala Siripan, Pretikul Nisa, Boonsiri Metavee, Sangob Naruemon, Rattanakaemakorn Ploysyne
Аннотация
INTRODUCTION: Real-world data on secukinumab use in Thai patients with psoriasis is limited. This study evaluates its effectiveness and safety in routine clinical practice.
METHODS: The PROMPT study is an ongoing, multicenter, 2-year observational study involving patients with moderate to severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), or ankylosing spondylitis (AS) treated with secukinumab. This interim analysis reports one-year outcomes in patients with plaque PsO.
RESULTS: A total of 101 patients with moderate to severe plaque PsO were included. The one-year secukinumab retention rate was 80% (95% CI: 75-88%). The most common reasons for discontinuation were financial constraints and lack of reimbursement. Effectiveness outcomes showed a significant reduction in psoriasis area and severity index (PASI) scores, with a mean percentage change of -84% (95% CI: -88 to -79%), and 77 patients achieved PASI 75. Physician's global assessment (PGA) scores also improved significantly, with a median score of 1.0 at 12 months. Health-related quality of life (HRQoL) improved, with a mean utility score increase of 0.2 (95% CI: 0.1-0.2) and a mean DLQI score reduction of -80% (95% CI: -85 to -75%). Only three patients reported adverse drug events, with no serious adverse events observed.
CONCLUSION: Secukinumab demonstrated one-year retention comparable to previous real-world studies, with a favorable safety profilein Thai patients with moderate to severe plaque psoriasis. It significantly improved disease severity and HRQoL in real-world clinical settings.
METHODS: The PROMPT study is an ongoing, multicenter, 2-year observational study involving patients with moderate to severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), or ankylosing spondylitis (AS) treated with secukinumab. This interim analysis reports one-year outcomes in patients with plaque PsO.
RESULTS: A total of 101 patients with moderate to severe plaque PsO were included. The one-year secukinumab retention rate was 80% (95% CI: 75-88%). The most common reasons for discontinuation were financial constraints and lack of reimbursement. Effectiveness outcomes showed a significant reduction in psoriasis area and severity index (PASI) scores, with a mean percentage change of -84% (95% CI: -88 to -79%), and 77 patients achieved PASI 75. Physician's global assessment (PGA) scores also improved significantly, with a median score of 1.0 at 12 months. Health-related quality of life (HRQoL) improved, with a mean utility score increase of 0.2 (95% CI: 0.1-0.2) and a mean DLQI score reduction of -80% (95% CI: -85 to -75%). Only three patients reported adverse drug events, with no serious adverse events observed.
CONCLUSION: Secukinumab demonstrated one-year retention comparable to previous real-world studies, with a favorable safety profilein Thai patients with moderate to severe plaque psoriasis. It significantly improved disease severity and HRQoL in real-world clinical settings.